Overview

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

Status:
Active, not recruiting

Trial end date:
2024-10-01

Target enrollment:

Participant gender:

Summary

This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis

Phase:

Phase 2

Details

Lead Sponsor:

Escient Pharmaceuticals, Inc